Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JHSF Report Shows Large Gap between US and Japan in Bio Industry
April 16, 2001
- Lilly's Evista Reduces Risk of Heart Disease: MORE Trial
April 16, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 16, 2001
- Kokuho Balance of Payment Records Deficit of \120.8 Bil. in FY1999
April 16, 2001
- Sun Drug, Kawachi Yakuhin to Remain Highly Profitable: Nomura Report
April 16, 2001
- Grand Design for Social Security Reform Announced by Gov't, Ruling Coalition
April 16, 2001
- Jovi, Wing to Merge on October 1
April 16, 2001
- 15 New Active Ingredients Including Gemzar, Zyvox Approved
April 16, 2001
- Kirin-do: Double-digit Increases in Sales, Profits
April 16, 2001
- Criteria for Disclosure, Non-disclosure Published
April 16, 2001
- MEDICAL DEVICE NEWS IN BRIEF
April 16, 2001
- Hitachi, Myriad, Oracle, Friedli to Tie Up in Proteomics
April 16, 2001
- JPA Leader Comments on New Deregulation Promotion Plan
April 16, 2001
- Sankyo to Be Aggressive in Genomic Drug Discovery: Dr Hiraoka
April 16, 2001
- Toyama to Exclusively Market YP-14 Jointly Developed with Taiho
April 16, 2001
- Review of NHI Price System Included in New Deregulation Plan
April 16, 2001
- Daiichi, Medtronic Codevelop Intrathecal Baclofen Therapy
April 16, 2001
- Novartis to Double Sales in 5 Years in Transplantation, Immunology, Cancer
April 16, 2001
- REGULATORY NEWS IN BRIEF -1-
April 16, 2001
- Kirin Brewery to Survive by Focusing on Cancer, Nephrology, Allergy/Immunology
April 16, 2001
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…